Project R-15206

Advancing precision oncology: Plasma-treated hydrogels as a targeted therapy for head and neck cancer (Research)

This project proposes an innovative approach using thermosensitive plasma-activated hydrogels (PAHs) as a new treatment for head and neck cancer (HNC). Utilizing PAHs as carriers for plasmainduced reactive oxygen and nitrogen species (RONS), this study aims to surpass the current HNC treatment standards by selectively eradicating tumor cells while sparing healthy tissue. Conventional treatment such as surgery, radiotherapy, chemotherapy, or their combination causes severe systemic side effects and still lead to poor prognosis. Firstly, 2D and 3D in vitro systems are used to evaluate PAH efficacy on cancer and healthy cells. Next, the efficacy of PAH treatment is assessed in an HNC xenograft mouse model. Non-invasive imaging will be used to visualize PAH effects over time, assessing tumor reduction and impact on recurrence post-resection. Finally, the efficacy of PAH treatment is assessed in the 4NQO mouse model, simulating human-like HNC development. Noninvasive imaging will be used to evaluate PAH effectiveness, providing insights into PAH-induced cancer cell death and immunotherapeutic effects. This project aims to establish the efficiency and selectivity of thermosensitive PAHs as a therapeutic approach against HNC, with potential implications for preventing tumor recurrence. The interdisciplinary nature and collaboration with plasma technology experts contribute to its uniqueness and potential impact on advancing precision oncology.

01 November 2024 - 31 October 2028